Missing Conflict of Interest Disclosure.
出版信息
JAMA Oncol. 2018 Oct 1;4(10):1439. doi: 10.1001/jamaoncol.2018.4091.
Abstract
摘要
相似文献
1
Missing Conflict of Interest Disclosure.利益冲突披露缺失。
JAMA Oncol. 2018 Oct 1;4(10):1439. doi: 10.1001/jamaoncol.2018.4091.
2
Survey of conflict-of-interest disclosure policies of ophthalmology journals.眼科期刊利益冲突披露政策调查。
Ophthalmology. 2009 Jun;116(6):1093-6. doi: 10.1016/j.ophtha.2008.12.053. Epub 2009 Apr 19.
3
Society for Maternal-Fetal Medicine Special Statement: Society for Maternal-Fetal Medicine's conflict of interest policy.母胎医学会特别声明：母胎医学会的利益冲突政策。
Am J Obstet Gynecol. 2020 Dec;223(6):B47-B57.e3. doi: 10.1016/j.ajog.2020.09.025. Epub 2020 Sep 22.
4
Reporting of conflicts of interest in oral presentations at medical conferences: a delegate-based prospective observational study.医学会议口头报告中利益冲突的报告：一项基于代表的前瞻性观察性研究。
BMJ Open. 2017 Sep 21;7(9):e017019. doi: 10.1136/bmjopen-2017-017019.
5
Conflict of interest disclosure in obstetrics & gynecology.妇产科的利益冲突披露。
Obstet Gynecol. 2011 Nov;118(5):1108-1110. doi: 10.1097/AOG.0b013e31823402f6.
6
Insinuation Anxiety: Concern That Advice Rejection Will Signal Distrust After Conflict of Interest Disclosures.暗示性焦虑：在披露利益冲突后，担心拒绝建议会暗示不信任。
Pers Soc Psychol Bull. 2019 Jul;45(7):1099-1112. doi: 10.1177/0146167218805991. Epub 2018 Nov 17.
7
Conflict of Interest Disclosure in a Top-Tier Portuguese Medical Journal.葡萄牙顶级医学期刊中的利益冲突披露
Acta Med Port. 2017 Sep 29;30(9):652-655. doi: 10.20344/amp.8458.
8
[Conflict of interest policies and disclosure requirements among European Society of Cardiology national cardiovascular journals].[欧洲心脏病学会各国心血管杂志的利益冲突政策与披露要求]
Arch Cardiol Mex. 2012 Apr-Jun;82(2):170-80.
9
Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals.欧洲心脏病学会各国家心血管杂志的利益冲突政策及披露要求
Rev Esp Cardiol (Engl Ed). 2012 May;65(5):471-8. doi: 10.1016/j.recesp.2012.02.002. Epub 2012 Mar 30.
10
[Conflict of interest and disclosures to academic meetings and journals].[利益冲突及向学术会议和期刊披露的情况]
Rinsho Ketsueki. 2020;61(9):1013-1017. doi: 10.11406/rinketsu.61.1013.
本文引用的文献
1
Inconsistent Reporting of Potential Conflicts of Interest.潜在利益冲突报告不一致。
JAMA Oncol. 2018 Oct 1;4(10):1439. doi: 10.1001/jamaoncol.2018.3461.
2
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.估算接受基于基因组的肿瘤学治疗的美国癌症患者的百分比。
JAMA Oncol. 2018 Aug 1;4(8):1093-1098. doi: 10.1001/jamaoncol.2018.1660.
3
Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.嵌合抗原受体 T 细胞免疫疗法的总费用。
JAMA Oncol. 2018 Jul 1;4(7):994-996. doi: 10.1001/jamaoncol.2018.0977.
4
Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.基于生物标志物而非肿瘤类型获批的癌症药物——美国食品药品监督管理局批准帕博利珠单抗用于错配修复缺陷实体癌
JAMA Oncol. 2018 Feb 1;4(2):157-158. doi: 10.1001/jamaoncol.2017.4182.
5
Overall Survival vs Disease-Specific Survival-Reply.总生存期与疾病特异性生存期——回复
JAMA Oncol. 2018 Apr 1;4(4):586-587. doi: 10.1001/jamaoncol.2017.3865.
6
Is "Do Everything!" Always Appropriate?-Reply.“全力以赴！”总是合适的吗？——回复
JAMA Oncol. 2017 Nov 1;3(11):1588. doi: 10.1001/jamaoncol.2017.2349.
7
Pemetrexed in Nonsquamous Non-Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis.培美曲塞用于非鳞状非小细胞肺癌：十亿美元的亚组分析
JAMA Oncol. 2018 Jan 1;4(1):17-18. doi: 10.1001/jamaoncol.2017.1944.
8
Overestimating the Benefit of Cancer Drugs.高估癌症药物的益处。
JAMA Oncol. 2017 Dec 1;3(12):1737-1738. doi: 10.1001/jamaoncol.2017.0107.
Zotero 插件